The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death. Treatment with direct-acting antiviral agents (DAAs) contributes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Irina RUSU, Liliana HODOROGEA, Tiberiu HOLBAN
Formato:	article
Lenguaje:	EN FR RO RU
Publicado:	Asociatia de Biosiguranta si Biosecuritate 2020
Materias:	chronic hcv treatment sofosbuvir ledipasvir daclatasvir Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6662844190594fddbe05c29baf17225b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6662844190594fddbe05c29baf17225b
record_format	dspace
spelling	oai:doaj.org-article:6662844190594fddbe05c29baf17225b2021-12-02T10:37:31ZThe efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C10.38045/ohrm.2020.1.022887-34582587-3466https://doaj.org/article/6662844190594fddbe05c29baf17225b2020-03-01T00:00:00Zhttps://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/25/11https://doaj.org/toc/2887-3458https://doaj.org/toc/2587-3466Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death. Treatment with direct-acting antiviral agents (DAAs) contributes to a sustained virological response (SVR) in 97-99% of cases. Material and methods. The study was conducted on 206 patients with chronic HCV who underwent two generic antiviral agent therapies: group I (103) – Sofosbuvir 400 mg + Ledipasvir 80 mg, whereas group II (103) – Sofosbuvir 400 mg + Daclatasvir 60 mg orally, once a day, for 12 weeks. The assessment of hepatitis C virus RNA and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count (CBC) indices, were carried out. Results. The study results showed a high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and 86.4% – in Sofosbuvir + Daclatasvir. A similar treatment response was recorded in naive patients and those who previously underwent unsuccessful treatment with Pegylated Interferon and Ribavirin. The DAAs treatment showed the following minor adverse reactions: asthenia, headache, sleep disorder, and nausea, which did not require treatment discontinuation. Conclusions. The 12-week course of DAAs therapy exhibited a high SVR rate in both chronic HCV naive patients and those previously treated with Pegylated Interferon and Ribavirin.Irina RUSULiliana HODOROGEATiberiu HOLBANAsociatia de Biosiguranta si Biosecuritatearticlechronic hcvtreatmentsofosbuvirledipasvirdaclatasvirMedicineRScienceQENFRRORUOne Health & Risk Management, Vol 1, Iss 1, Pp 4-11 (2020)
institution	DOAJ
collection	DOAJ
language	EN FR RO RU
topic	chronic hcv treatment sofosbuvir ledipasvir daclatasvir Medicine R Science Q
spellingShingle	chronic hcv treatment sofosbuvir ledipasvir daclatasvir Medicine R Science Q Irina RUSU Liliana HODOROGEA Tiberiu HOLBAN The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
description	Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death. Treatment with direct-acting antiviral agents (DAAs) contributes to a sustained virological response (SVR) in 97-99% of cases. Material and methods. The study was conducted on 206 patients with chronic HCV who underwent two generic antiviral agent therapies: group I (103) – Sofosbuvir 400 mg + Ledipasvir 80 mg, whereas group II (103) – Sofosbuvir 400 mg + Daclatasvir 60 mg orally, once a day, for 12 weeks. The assessment of hepatitis C virus RNA and genotype, as well as the degree of hepatic fibrosis by Fibroscan, biochemical and complete blood count (CBC) indices, were carried out. Results. The study results showed a high efficacy of the generic DAAs treatment in patients with chronic HCV over 12 weeks. The SVR rate made up 90.3% in Sofosbuvir + Ledipasvir therapy and 86.4% – in Sofosbuvir + Daclatasvir. A similar treatment response was recorded in naive patients and those who previously underwent unsuccessful treatment with Pegylated Interferon and Ribavirin. The DAAs treatment showed the following minor adverse reactions: asthenia, headache, sleep disorder, and nausea, which did not require treatment discontinuation. Conclusions. The 12-week course of DAAs therapy exhibited a high SVR rate in both chronic HCV naive patients and those previously treated with Pegylated Interferon and Ribavirin.
format	article
author	Irina RUSU Liliana HODOROGEA Tiberiu HOLBAN
author_facet	Irina RUSU Liliana HODOROGEA Tiberiu HOLBAN
author_sort	Irina RUSU
title	The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
title_short	The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
title_full	The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
title_fullStr	The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
title_full_unstemmed	The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
title_sort	efficacy of direct-acting antiviral therapy in patients with chronic hepatitis c
publisher	Asociatia de Biosiguranta si Biosecuritate
publishDate	2020
url	https://doaj.org/article/6662844190594fddbe05c29baf17225b
work_keys_str_mv	AT irinarusu theefficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc AT lilianahodorogea theefficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc AT tiberiuholban theefficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc AT irinarusu efficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc AT lilianahodorogea efficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc AT tiberiuholban efficacyofdirectactingantiviraltherapyinpatientswithchronichepatitisc
_version_	1718396931189768192

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C

Ejemplares similares